in cb1 -/-mice, backcrossed to C57Bl/6J mice (C57 CB1-/-mice), revealed low bone mass (LBM). We therefore analyzed CB1 expression in bone and compared the skeletons of sexually mature C57 CB1-/-and CD1 CB1-/-mice in the same experimental setting. CB1 mRNA is weakly expressed in osteoclasts and immunoreactive CB1 is present in sympathetic neurons, close to osteoblasts. In addition to their LBM, male and female C57 CB1-/-mice exhibit decreased bone formation rate and increased osteoclast number. The skeletal phenotype of the CD1 CB1-/-mice shows a gender disparity. Females have normal trabecular bone with a slight cortical expansion, whereas male CD1 CB1-/-animals display a HBM phenotype.
Surprisingly, bone formation and resorption are within normal limits. These findings, at least the consistent set of data obtained in the C57 CB1-/-line, suggest an important role for CB1 signalling in the regulation of bone remodelling and bone mass. Because sympathetic CB1
signalling inhibits norepinephrine (NE) release in peripheral tissues, part of the endocannabinoid activity in bone may be attributed to the regulation of NE release from sympathetic nerve fibers. Several phenotypic discrepancies have been reported between C57 CB1-/-and CD1 CB1-/-mice, which could result from genetic differences between the background strains. Unraveling these differences can provide useful information on the physiologic functional milieu of CB1 in bone.
This article has not been copyedited and formatted. The final version may differ from this version. 
4
The endogenous cannabinoids bind to and activate the CB1 and CB2 cannabinoid receptors. Both are seven-transmembrane domain receptors which share 44% identity. They are coupled to the Gi/o subclass of G-proteins and inhibit stimulated adenylyl cyclase activity (Rhee et al., 1997) . CB1 is present in the brain and in peripheral neurons and accounts for most of the central nervous system actions of cannabinoid drugs and endocannabinoids (Herkenham et al., 1990; Zimmer et al., 1999) . CB2 is found mainly in the immune system (Munro et al., 1993) .
In vertebrates, bone mass and shape are determined by continuous remodeling consisting of the concerted and balanced action of osteoclasts, the bone resorbing cells, and osteoblasts, the bone forming cells. Osteoporosis, the most prevalent degenerative disease in developed countries, results from impaired remodeling balance, which leads to bone loss and increased fracture risk. It has been recently reported that bone remodeling is subject to central control through pathways that involve signaling by the hypothalamic receptors for leptin and neuropeptide Y ( Ducy et al., 2000; Baldock et al., 2002) , which are also associated with the regulation of endocannabinoid brain levels (Di Marzo et al., 2001) . Along these lines we have recently reported that (i) the peripheral CB2 cannabinoid receptor is normally expressed in osteoblasts, osteoclasts and in their precursors; (ii) mice deficient for CB2 have a low bone mass (LBM) phenotype; (iii) specific activation of CB2 attenuates ovariectomy-induced bone loss by restraining osteoclastogenesis and stimulating bone formation (Ofek et al., 2006) .
Two mutant mouse lines with deficiency in the CB1 gene have been generated. In one line, backcrossed to C57Bl/6J mice (C57 CB1-/-), almost the entire protein-encoding sequence was removed (Zimmer et al., 1999) . In the other line, backcrossed to CD1 mice (CD1 CB1-/-), the N-terminal 233 codons of cb1 were ablated (Ledent et al., 1999) . Although both lines demonstrate a null mutation missing all the CB1 responsiveness to cannabinoid ligands, they display significant phenotypic discrepancies (Lutz, 2002; Hoffman et al., 2005) . Regarding
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Materials and Methods
Animals. All animals in the study were 9 to 12-week-old mice. C57 CB1-/-mice were generated as reported previously (Zimmer et al., 1999) . We have crossed heterozygous animals of this line for at least 10 generations to WT C57BL/6J mice. Heterozygous animals from the last generation were then intercrossed to obtain congenic C57BL/6J mice that are homozygous for the respective mutation. CD1 CB1-/-mice were generated by homologous recombination as described previously (Ledent et al., 1999) . Heterozygous mice were bred for 17 generations on a CD1 background before generating the WT and cb1 null littermates used in this study. To study bone formation, newly formed bone was vitally labelled in mice intended for micro-computed tomographic (µCT)-histomorphometric analysis by the fluorochrome calcein (Sigma), injected intraperitoneally (15 mg/Kg) four days and one day prior to sacrifice. The use of animals was approved by the Institutional Animal Care
Committee of the Hebrew University of Jerusalem.
Immunohistochemistry. Mice were killed by transcardial perfusion of phosphate buffered saline followed by 4% parafomaldehyde. The femora were dissected and further fixed with parafomaldehyde for 2 h at 4°C. The specimens were decalcified in 0.5 M EDTA, pH 7.4 and embedded in paraffin. For immunohistochemical analysis, 5 µm serial frontal sections were reacted with anti-tyrosine hydroxylase (TH) (Chemicon, Temecula, CA) or anti-CB1 antibodies (Nyíri et al., 2005) . Further processing was carried out using the SuperPicture™ Polymer detection Kit (Zymed Laboratories, San Francisco, CA; cat no. 87-9263) according to the manufacturer instructions.
Cell cultures and mRNA analysis. Primary bone marrow stromal cell cultures from WT adult femoral and tibial diaphyseal bone marrow were established as previously described. For testing CB1 expression, the cells were grown in osteogenic medium (Ofek et al, 2006) . Bone marrow derived osteoclastogenic cultures were established from ficollThis article has not been copyedited and formatted. The final version may differ from this version. parathyroid hormone receptor I (PTH-Rc1), sense: 5'-CAAGAAGTGGATCATCCAGGT-3',
Microcomputed Tomographic (µCT) Analysis. Whole femora were examined by a µCT system (µCT 40, SCANCO Medical, Bassersdorf, Switzerland) as reported recently (Bajayo et al., 2005; Ofek et al., 2006) . Scans were performed at a resolution of 20 µm in all three spatial dimensions. Morphometric parameters were determined as reported previously . Trabecular and cortical bone parameters were measured in metaphyseal and mid-diaphyseal segments, respectively.
Histomorphometry. After µCT image acquisition, the specimens were embedded undecalcified in Technovit 9100 (Heraeus). Longitudinal sections through the midfrontal plane were left unstained for dynamic histomorphometry, based on the vital calcein double labeling. To identify osteoclasts, consecutive sections were stained for tartrate-resistant acid phosphatase (TRAP). Parameters were determined according to a standardized nomenclature (Parfitt et al., 1987) .
Statistical analysis. Differences between cb1
-/-and WT mice were analyzed by the Student's t-test.
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Results and Discussion
Expression of CB1 in bone. mRNA analyses were carried out in cells derived from WT C57Bl/6J mice. Unlike the expression of CB2, which is absent in undifferentiated bone marrow stromal cells, but increases progressively when these cells undergo osteoblastic differentiation (Ofek et al., 2006) , we were unable to identify CB1 mRNA transcripts in either undifferentiated or differentiated stromal cells, even after 40 PCR cycles (Fig. 1A) .
Monocytic osteoclast precursors from these mice also did not show CB1 expression. Yet, a weak signal was present when these cells underwent osteoclastogenesis with M-CSF and RANKL (Fig. 1B) .
Bone, especially trabecular, is densely innervated by sympathetic fibers (Serre et al, 1999; Mach et al., 2002) . These fibers release norepinephrine (NE), thus potently mediating central signals that restrain bone formation and stimulate bone resorption (Elefteriou et al., 2005) . Because CB1 is expressed in such nerve fibers elsewhere (Schlicker and Kathmann, 2001 ), we further explored its presence in bone sympathetic nerve fibers. Indeed, immunohistochemical analysis using the sympathetic marker TH (Bjurholm et al., 1988) confirmed the occurrence of a network of TH-positive fibers in the inter-trabecular spaces of cancellous bone in both C57Bl/6J and CD1 mice (Figs. 1C, 1G ). The fibers were close to the bone trabeculae with terminal nerve processes penetrating the osteoblast palisades, thus being in intimate proximity to these cells (Figs. 1D, 1G ). Consecutive histological sections show CB1 immunoreactivity of the same nerve fibers (Figs. 1E, 1F, 1H ), indicating the presence of CB1 receptors in sympathetic fibers that innervate the trabecular bone. This CB1 immunoreactivity was missing in the CB1-null mice (data not shown). Compared to their WT controls, both male and female C57 CB1-/-mice exhibited low bone mass (LBM) phenotype characterized by a lower density of their trabecular network.
The trabecular bone volume density (BV/TV) in female and male null mice was lower by 20% and 15% than that of WT C57Bl/6J controls, respectively (Fig. 2) . Apparently, the lower BV/TV in the C57 CB1-/-mice resulted from decreases in the trabecular number (Fig. 3A) without changes in the trabecular thickness (Tb.Th) (Fig. 3B) . The trabecular connectivity density, a parameter measuring the structural integrity of the trabecular network (Stampa et al., 2002) , was also decreased in these animals ( Fig. 3C ) but did not reach statistical difference. Also, both the diaphyseal shaft diameter (Dia.Dia) and medullary cavity diameter (Med.Dia) were narrower in the C57 CB1-/-mice ( Fig. 4A & 4B) , with unchanged cortical thickness (Fig. 4C ).
By contrast, the CD1 CB1-/-skeletal phenotype showed a marked gender bias. The trabecular bone, the main skeletal compartment affected in osteoporosis, appears normal in female CD1 CB1-/-mice (Figs. 2, 3D-3F ). Male CD1 CB1-/-mice had a pronounced HBM phenotype demonstrating 27.5% increase in trabecular BV/TV (Fig. 2) accompanied by increased Tb.Th (Fig. 3E ) and slightly decreased connectivity density (Fig. 3F) . The female CD1 CB1-/-diaphysis was mildly abnormal, exhibiting cortical expansion portrayed as increases in both Dia.Dia and Med.Dia (Figs. 4D, 4E ). The male CD1 CB1-/-diaphysis appeared normal (Fig. 4D-4F ).
To gain further insight into the processes leading to the LBM phenotype in C57
CB1-/-mice, we analyzed their bone remodelling. Consistent with the results of the structural µCT parameters, the histomorphometric analysis demonstrated that the LBM in these mice is associated with unbalanced bone remodelling. The bone formation rate (BFR) was markedly This article has not been copyedited and formatted. The final version may differ from this version. 10 decreased in both females and males (Fig. 5A) , mainly due to a decrease in mineral appositional rate, a surrogate of osteoblast activity (Fig. 5B) , inasmuch as the mineralizing perimeter, a surrogate of osteoblast number, remains unchanged (Fig. 5C ). The osteoclast number was increased, significantly in females and insignificantly in males (Fig. 5D ).
Unexpectedly, we could not find any significant differences in bone remodelling parameters between the CD1 CB1-/-mice and their WT controls, even not in males (Table 1) . Jointly these results suggest that in the C57Bl/6J mice, CB1 signalling positively regulates trabecular bone mass and radial diaphyseal growth by up regulating bone formation and down regulating bone resorption. The absence of significant changes in bone remodelling parameters of the male CD1 CB1-/-mice suggests that CB1 in these animals is associated only with the accrual of peak bone mass, which occurs at a younger age than that studied here. Apparently, the LBM phenotype is exhibited in the C57 CB1-/-mice consequent to a decrease in bone formation and increase in bone resorption attributable to the absence of sympathetic CB1, which normally inhibits NE release (Ishac et al., 1996) .
Although either genetic modification lead to a null mutation missing all CB1 responsiveness to its ligands, the occurrence of phenotypic differences is not entirely surprising, inasmuch as these mouse lines exhibit other substantial discrepancies ranging from nociceptive perception to locomotor activity, life expectancy and embryo implantation (Lutz, 2002) . Furthermore, at least to some extent, skeletal dissimilarity between the C57 CB1-/-and CD1 CB1-/-mice could be expected from the differences in bone mass and structure observed between the WT CD1 and C57Bl/6J background strains. More surprising is the gender bias portrayed by the CD1 CB1-/-mice and the absence of changes in bone remodeling in male animals that could explain their HBM. Although a HBM phenotype, unaccompanied by changes in bone remodeling, was reported previously (Idris et al., 2005) , it is unclear to us whether it was assigned to males, females or both.
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In spite of the differences between the two mouse lines, the present findings, especially the consistency in C57 CB1-/-mice presented by (i) CB1 expression in bone; (ii) LBM; and (iii) changes in skeletal turnover parameters, suggest a role for sympathetic CB1 in the control of bone remodeling and bone mass. In fact, unraveling the genetic differences between the C57Bl/6J and CD1 strains, as well as the genetic basis for the gender discrimination within the CD1 CB1-/-mouse line, can provide useful information on the physiologic functional milieu of CB1 in bone. Until an explanation for the skeletal (and possibly other) differences between the C57 CB1-/-and CD1 CB1-/-mice is found, it is our approach that only experimental trends shared by both mouse lines should be considered.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
